pubmed-article:11120792 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:11120792 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
pubmed-article:11120792 | lifeskim:mentions | umls-concept:C0025936 | lld:lifeskim |
pubmed-article:11120792 | lifeskim:mentions | umls-concept:C0003320 | lld:lifeskim |
pubmed-article:11120792 | lifeskim:mentions | umls-concept:C1762617 | lld:lifeskim |
pubmed-article:11120792 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
pubmed-article:11120792 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
pubmed-article:11120792 | lifeskim:mentions | umls-concept:C1414550 | lld:lifeskim |
pubmed-article:11120792 | lifeskim:mentions | umls-concept:C1414551 | lld:lifeskim |
pubmed-article:11120792 | lifeskim:mentions | umls-concept:C1414552 | lld:lifeskim |
pubmed-article:11120792 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
pubmed-article:11120792 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
pubmed-article:11120792 | lifeskim:mentions | umls-concept:C0599894 | lld:lifeskim |
pubmed-article:11120792 | pubmed:issue | 12 | lld:pubmed |
pubmed-article:11120792 | pubmed:dateCreated | 2000-12-21 | lld:pubmed |
pubmed-article:11120792 | pubmed:abstractText | Previous studies have documented that targeting foreign Ags to IgG FcgammaR leads to enhanced Ag-specific responses in vitro and in vivo. However, the ability to overcome immunologic nonresponsiveness by targeting poorly immunogenic Ags to FcgammaR has not been investigated. To address this question in a simple model, we immunized transgenic mice expressing human CD64 (FcgammaRI) and their nontransgenic littermates with Fab' derived from the murine anti-human CD64 mAb m22. The m22 Fab' served as both the targeting molecule and the Ag. We found that only CD64-expressing mice developed anti-Id titers to m22. Furthermore, chemically linked multimers of m22 Fab', which mediated efficient internalization of the human CD64, were significantly more potent than monomeric m22 F(ab')(2) at inducing anti-Id responses. In all cases, the humoral responses were specific for m22 Id and did not react with other murine IgG1 Fab' fragments. Chemical addition of a second murine Fab' (520C9 anti-human HER2/neu) to m22 Fab' multimers demonstrated that IgG1 and IgG2a anti-Id titers could be generated to 520C9 only in the CD64-expressing mice. These results show that targeting to CD64 can overcome immunological nonresponsiveness to a weak immunogen. Therefore, targeting to CD64 may be an effective method to enhance the activity of nonimmunogenic tumor vaccines. | lld:pubmed |
pubmed-article:11120792 | pubmed:language | eng | lld:pubmed |
pubmed-article:11120792 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11120792 | pubmed:citationSubset | AIM | lld:pubmed |
pubmed-article:11120792 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11120792 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11120792 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11120792 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11120792 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11120792 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11120792 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11120792 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11120792 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:11120792 | pubmed:month | Dec | lld:pubmed |
pubmed-article:11120792 | pubmed:issn | 0022-1767 | lld:pubmed |
pubmed-article:11120792 | pubmed:author | pubmed-author:FeeW WWW | lld:pubmed |
pubmed-article:11120792 | pubmed:author | pubmed-author:GuyreP MPM | lld:pubmed |
pubmed-article:11120792 | pubmed:author | pubmed-author:GrazianoR FRF | lld:pubmed |
pubmed-article:11120792 | pubmed:author | pubmed-author:KelerTT | lld:pubmed |
pubmed-article:11120792 | pubmed:author | pubmed-author:VitaleL ALA | lld:pubmed |
pubmed-article:11120792 | pubmed:author | pubmed-author:Sundarapandiy... | lld:pubmed |
pubmed-article:11120792 | pubmed:author | pubmed-author:van De... | lld:pubmed |
pubmed-article:11120792 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:11120792 | pubmed:day | 15 | lld:pubmed |
pubmed-article:11120792 | pubmed:volume | 165 | lld:pubmed |
pubmed-article:11120792 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:11120792 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:11120792 | pubmed:pagination | 6738-42 | lld:pubmed |
pubmed-article:11120792 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
pubmed-article:11120792 | pubmed:meshHeading | pubmed-meshheading:11120792... | lld:pubmed |
pubmed-article:11120792 | pubmed:meshHeading | pubmed-meshheading:11120792... | lld:pubmed |
pubmed-article:11120792 | pubmed:meshHeading | pubmed-meshheading:11120792... | lld:pubmed |
pubmed-article:11120792 | pubmed:meshHeading | pubmed-meshheading:11120792... | lld:pubmed |
pubmed-article:11120792 | pubmed:meshHeading | pubmed-meshheading:11120792... | lld:pubmed |
pubmed-article:11120792 | pubmed:meshHeading | pubmed-meshheading:11120792... | lld:pubmed |
pubmed-article:11120792 | pubmed:meshHeading | pubmed-meshheading:11120792... | lld:pubmed |
pubmed-article:11120792 | pubmed:meshHeading | pubmed-meshheading:11120792... | lld:pubmed |
pubmed-article:11120792 | pubmed:meshHeading | pubmed-meshheading:11120792... | lld:pubmed |
pubmed-article:11120792 | pubmed:meshHeading | pubmed-meshheading:11120792... | lld:pubmed |
pubmed-article:11120792 | pubmed:meshHeading | pubmed-meshheading:11120792... | lld:pubmed |
pubmed-article:11120792 | pubmed:meshHeading | pubmed-meshheading:11120792... | lld:pubmed |
pubmed-article:11120792 | pubmed:meshHeading | pubmed-meshheading:11120792... | lld:pubmed |
pubmed-article:11120792 | pubmed:meshHeading | pubmed-meshheading:11120792... | lld:pubmed |
pubmed-article:11120792 | pubmed:meshHeading | pubmed-meshheading:11120792... | lld:pubmed |
pubmed-article:11120792 | pubmed:meshHeading | pubmed-meshheading:11120792... | lld:pubmed |
pubmed-article:11120792 | pubmed:meshHeading | pubmed-meshheading:11120792... | lld:pubmed |
pubmed-article:11120792 | pubmed:meshHeading | pubmed-meshheading:11120792... | lld:pubmed |
pubmed-article:11120792 | pubmed:meshHeading | pubmed-meshheading:11120792... | lld:pubmed |
pubmed-article:11120792 | pubmed:year | 2000 | lld:pubmed |
pubmed-article:11120792 | pubmed:articleTitle | Targeting weak antigens to CD64 elicits potent humoral responses in human CD64 transgenic mice. | lld:pubmed |
pubmed-article:11120792 | pubmed:affiliation | Medarex, Inc., Annandale, NJ 08801, USA. tkeler@injersey.com | lld:pubmed |
pubmed-article:11120792 | pubmed:publicationType | Journal Article | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11120792 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11120792 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11120792 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11120792 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11120792 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11120792 | lld:pubmed |